Abstract:Background: CaMKII (Ca2+/calmodulin-dependent kinase II) plays a central role in cardiac ischemia/reperfusion (I/R) injury-an important therapeutic target for ischemic heart disease. In the heart, CaMKII-delta is the predominant isoform and further alternatively spliced into 11 variants. In humans, CaMKII-delta 9 and CaMKII-delta 3, the major cardiac splice variants, inversely regulate cardiomyocyte viability with the former pro-death and the latter pro-survival. However, it is unknown whether specific inhibition of the detrimental CaMKII-delta 9 prevents cardiac I/R injury and, if so, what is the underlying mechanism. Here, we aim to investigate the cardioprotective effect of specific CaMKII-delta 9 inhibition against myocardial I/R damage and determine the underlying mechanisms. Methods: The role and mechanism of CaMKII-delta 9 in cardiac I/R injury were investigated in mice in vivo, neonatal rat ventricular myocytes, and human embryonic stem cell-derived cardiomyocytes. Results: We demonstrate that CaMKII-delta 9 inhibition with knockdown or knockout of its feature exon, exon 16, protects the heart against I/R-elicited injury and subsequent heart failure. I/R-induced cardiac inflammation was also ameliorated by CaMKII-delta 9 inhibition, and compared with the previously well-studied CaMKII-delta 2, CaMKII-delta 9 overexpression caused more profound cardiac inflammation. Mechanistically, in addition to IKK beta (inhibitor of NF-kappa B [nuclear factor-kappa B] kinase subunit beta), CaMKII-delta 9, but not delta 2, directly interacted with I kappa B alpha (NF-kappa B inhibitor alpha) with its feature exon 13-16-17 combination and increased I kappa B alpha phosphorylation and consequently elicited more pronounced activation of NF-kappa B signaling and inflammatory response. Furthermore, the essential role of CaMKII-delta 9 in myocardial inflammation and damage was confirmed in human cardiomyocytes. Conclusions: We not only identified CaMKII-delta 9-IKK/I kappa B-NF-kappa B signaling as a new regulator of human cardiomyocyte inflammation but also demonstrated that specifically targeting CaMKII-delta 9, the most abundant CaMKII-delta splice variant in human heart, markedly suppresses I/R-induced cardiac NF-kappa B activation, inflammation, and injury and subsequently ameliorates myocardial remodeling and heart failure, providing a novel therapeutic strategy for various ischemic heart diseases.

Cardiomyocyte IL-1R2 protects heart from ischemia/reperfusion injury by attenuating IL-17RA-mediated cardiomyocyte apoptosis

Cardiomyocyte IL-IR2 Protects Heart From Ischemia/Reperfusion Injury by Attenuating NLRP3 Inflammasome Activation and IL-17RA-Mediated Apoptosis

Ipla2β Contributes to ER Stress-Induced Apoptosis During Myocardial Ischemia/Reperfusion Injury

The Protective Role of Interleukin-18 Binding Protein in a Murine Model of Cardiac Ischemia/reperfusion Injury.

Recombinant Human Interleukin-1 Receptor Antagonist Treatment Protects Rats from Myocardial Ischemia–reperfusion Injury

Interleukin-17A Contributes to Myocardial Ischemia/reperfusion Injury by Regulating Cardiomyocyte Apoptosis and Neutrophil Infiltration.

Hypoxia-inducible Factor 2-Alpha-dependent Induction of IL-6 Protects the Heart from Ischemia/reperfusion Injury

Interleukin-17 Inhibition: an Important Target for Attenuating Myocardial Ischemia and Reperfusion Injury

Group 2 innate lymphoid cells protect mouse heart from myocardial infarction injury via interleukin 5, eosinophils, and dendritic cells

MiR-129-5p Protects Against Myocardial Ischemia-Reperfusion Injury Via Targeting HMGB1

Anti-IL-20 Antibody Protects against Ischemia/Reperfusion-Impaired Myocardial Function through Modulation of Oxidative Injuries, Inflammation and Cardiac Remodeling

The IL-2/Anti-IL-2 Complex Attenuates Cardiac Ischaemia-Reperfusion Injury Through Expansion of Regulatory T Cells

The Protective Role of Interleukin-33 in Myocardial Ischemia and Reperfusion Is Associated with Decreased HMGB1 Expression and Up-Regulation of the P38 MAPK Signaling Pathway.

IRG1 Prevents Excessive Inflammatory Responses and Cardiac Dysfunction after Myocardial Injury

Targeting CaMKII-9 Ameliorates Cardiac Ischemia/Reperfusion Injury by Inhibiting Myocardial Inflammation

Down-Regulation of Microrna-320 Suppresses Cardiomyocyte Apoptosis and Protects Against Myocardial Ischemia and Reperfusion Injury by Targeting Igf-1

Interleukin-27, a novel cytokine induced by ischemia–reperfusion injury in rat hearts, mediates cardioprotective effects via the gp130/STAT3 pathway

Cardiovascular Protective Effects of IL-1 Ra-Fc-il-18bp on Experimental Myocardial Infarction by Inhibiting Oxidative Stress and Inflammation in a Rat Model.

Up-regulation of PERK/Nrf2/HO-1 axis protects myocardial tissues of mice from damage triggered by ischemia-reperfusion through ameliorating endoplasmic reticulum stress

IL-33 Attenuates Anoxia/Reoxygenation-Induced Cardiomyocyte Apoptosis by Inhibition of PKCβ/JNK Pathway

Myocardial IGF2R is a Critical Mediator of Inflammation and Fibrosis after Ischemia-Reperfusion Injury.